#hepatocellular carcinoma

Checkpoint Immunotherapy Looks Promising for Operable Liver Cancer

October is Liver Cancer Awareness Month.

A study has identified a number of potential biomarkers that clinicians can use to predict how their patients will respond to treatment.

Imjudo plus Imfinzi improved overall survival compared with standard targeted therapy for hepatocellular carcinoma.

People with hepatocellular carcinoma had improved survival after the advent of direct-acting antiviral therapy.

However, people with liver cirrhosis remain at risk and should continue screening even after being cured.

New study supports U.S. guidelines for determining which people with liver cancer are eligible for a transplant.

Second- and third-generation individuals in Los Angeles had a 35% and 61% higher risk, respectively, than those born in Mexico.

The recent approval of several new medications has changed the treatment landscape.

“I’m glad to go to bat for the One Liver to Love initiative to encourage others to be proactive,” says Latino legend Bernie Williams.

The risk of HCC fell further as cumulative antihistamine use rose in people with HBV, HCV or both.

Liver cancer is now less likely to be caused by hepatitis B or C, but more likely to be caused by fatty liver disease or alcohol.

People who developed hepatocellular carcinoma after being cured of HCV had cirrhosis and worse liver function.

More than a third of hepatocellular carcinoma cases among Medicare recipients were due to fatty liver disease.

Cases of the most common type of liver cancer, hepatocellular carcinoma, are on the rise.

Hepatocellular carcinoma can still occur after hepatitis C is cured, and risk factors differ for people with and without cirrhosis.

Over the next two decades, obesity-linked NASH will lead to more deaths and high cost in the United States.